Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 1
Submit an article Journal homepage
1,174
Views
47
CrossRef citations to date
0
Altmetric
Research Article

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

Theodore R. JohnsonDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA, Correspondence[email protected]
,
Weiwei TanDepartment of Clinical Pharmacology, Pfizer Inc., San Diego, CA, USA,
,
Lance GouletDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
,
Evan B. SmithDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
,
Shinji YamazakiDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
,
Gregory S. WalkerDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT, USA,
,
Melissa T. O’GormanDepartment of Clinical Pharmacology, Pfizer Inc., Groton, CT, USA,
,
Gabriella BedaridaClinical Research Unit, Pfizer Inc., New Haven, CT, USA,
,
Helen Y. ZouOncology Research, Pfizer Inc., San Diego, CA, USA, and
,
James G. ChristensenOncology Research, Pfizer Inc., San Diego, CA, USA, and
,
Leslie N. NguyenDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
,
Zhongzhou ShenDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
,
Deepak DalvieDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
,
Akintunde BelloDepartment of Clinical Pharmacology, Pfizer Inc., New York, NY, USA
&
Bill J. SmithDepartment of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, CA, USA,
show all
Pages 45-59 | Received 09 May 2014, Accepted 02 Jul 2014, Published online: 18 Jul 2014

Citations (47)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Li Di. (2017) Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opinion on Drug Discovery 12:11, pages 1105-1115.
Read now
Peter N. Morcos, Li Yu, Katrijn Bogman, Mika Sato, Hisakazu Katsuki, Kosuke Kawashima, David J Moore, Matt Whayman, Keith Nieforth, Katja Heinig, Elena Guerini, Dieter Muri, Meret Martin-Facklam & Alex Phipps. (2017) Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica 47:3, pages 217-229.
Read now
Yi-chen Zhang, Qing Zhou & Yi-Long Wu. (2016) Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. Expert Opinion on Pharmacotherapy 17:12, pages 1693-1701.
Read now
C. M. Nijenhuis, J. H. M. Schellens & J. H. Beijnen. (2016) Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review. Drug Metabolism Reviews 48:2, pages 266-280.
Read now

Articles from other publishers (43)

Lan Chen, Yuan Zhang, Yi-Xin Zhang, Wei-Lai Wang, De-Mei Sun, Peng-Yun Li, Xue-Song Feng & Yue Tan. (2023) Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring. Journal of Pharmaceutical Analysis.
Crossref
Kihang Choi. (2023) The Structure–property Relationships of Clinically Approved Protein Kinase Inhibitors. Current Medicinal Chemistry 30:22, pages 2518-2541.
Crossref
Yutaka Fujiwara, Reiko Makihara, Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito, Yukari Tsubata, Takae Okuno, Toshiaki Takahashi, Haruki Kobayashi, Yuki Shinno, Yoshitaka Zenke, Takaya Ikeda, Yukio Hosomi, Kageaki Watanabe, Satoru Kitazono, Naomi Sakiyama, Yoshinori Makino & Noboru Yamamoto. (2023) Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight. Cancer Science 114:5, pages 2087-2097.
Crossref
Yakup Iriagac, Eyyup Cavdar, Kubilay Karaboyun, SeherYildiz Tacar, FatmaNihan Akkoc Mustafayev, Emir Celik, Okan Avci, SadiKerem Okutur, Lokman Koral, NebiSerkan Demirci, Alpaslan Ozgun & ErdoganSelcuk Seber. (2023) Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib. Journal of Cancer Research and Therapeutics 19:2, pages 376.
Crossref
Koushal BillowriaGhanshyam Das Gupta & Pooja A. Chawla. (2023) Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry 23:2, pages 124-141.
Crossref
Rameshwar S. Cheke, Pritam Bagwe, Shubham Bhange & Prashant S. Kharkar. 2023. Medicinal Chemistry of Chemotherapeutic Agents. Medicinal Chemistry of Chemotherapeutic Agents 615 646 .
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development 137 174 .
Malvika Sardana, Louise Breuil, Sébastien Goutal, Maud Goislard, Mikhail Kondrashov, Etienne Marchal, Florent L. Besson, Christophe Dugave, Gail Wrigley, Anna C. Jonson, Bertrand Kuhnast, Magnus Schou, Nicolas Tournier, Charles S. Elmore & Fabien Caillé. (2022) Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging. Pharmaceuticals 15:12, pages 1568.
Crossref
Qi Zhao, Zhanxuan E. Wu, Bin Li & Fei Li. (2022) Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacology & Therapeutics 237, pages 108256.
Crossref
Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali & Uppugunduri S. Chakradhara Rao. (2022) Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response. Pharmaceuticals 15:8, pages 990.
Crossref
Stefano Fogli, Fabrizio Tabbò, Annalisa Capuano, Marzia Del Re, Francesco Passiglia, Federico Cucchiara, Cristina Scavone, Veronica Gori, Silvia Novello, Manuela Schmidinger & Romano Danesi. (2022) The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. Critical Reviews in Oncology/Hematology 172, pages 103602.
Crossref
Huiping Xu, Melissa O'Gorman, Kyle Matschke, Tanya Boutros, Nicoletta Brega, Weiwei Tan & Akintunde Bello. (2021) Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants. Clinical Pharmacology in Drug Development 11:1, pages 34-42.
Crossref
W.M.A. Niessen, H. Rosing & J.H. Beijnen. (2021) Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites. International Journal of Mass Spectrometry 464, pages 116559.
Crossref
Nicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, Gerd Mikus, Antje Blank, Jürgen Burhenne, Michael Thomas & Walter E. Haefeli. (2020) Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. Clinical and Translational Science 14:2, pages 487-491.
Crossref
A.R. Bland, N. Shrestha, R.L. Bower, R.J. Rosengren & J.C. Ashton. (2021) The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochemical Pharmacology 183, pages 114345.
Crossref
Abhishek Tripathi, Jeffrey G. Supko, Kathryn P. Gray, Zachary J. Melnick, Meredith M. Regan, Mary-Ellen Taplin, Atish D. Choudhury, Mark M. Pomerantz, Joaquim Bellmunt, Channing Yu, Zijie Sun, Sandy Srinivas, Philip W. Kantoff, Christopher J. Sweeney & Lauren C. Harshman. (2020) Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research 26:23, pages 6122-6131.
Crossref
Sufeng Zhou, Wei Liu, Chen Zhou, Lingling Zhang, Lijun Xie, Zhaoqiang Xu, Lu Wang, Yuqing Zhao, Lian Guo, Juan Chen, Lieming Ding, Li Mao, Yi Tao, Chen Zhang, Sijia Ding & Feng Shao. (2020) Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. Cancer Chemotherapy and Pharmacology 86:6, pages 719-730.
Crossref
Mengli Wang, Qiuzheng Du, Lihua Zuo, Peng Xue, Chao Lan & Zhi Sun. (2020) Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo. Current Drug Metabolism 21:13, pages 996-1008.
Crossref
Ying Jiang, Zichao Yang, Lishun Zhang, Ruohong Yan, Siming Liu, Haikui Yang, Shanhe Wan, Zhonghuang Li, Zhengguang Zhu, Ling Ye & Jiajie Zhang. (2020) The cytochrome P450 metabolic profiling of SMU-B in vitro, a novel small molecule tyrosine kinase inhibitor. Journal of Pharmaceutical and Biomedical Analysis 188, pages 113400.
Crossref
Daria Stypinski, Luke Fostvedt, Justine L. Lam, Alfin Vaz, Theodore R. Johnson, Jan S. Boerma & Yazdi K. Pithavala. (2020) Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF‐06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies. The Journal of Clinical Pharmacology 60:9, pages 1254-1267.
Crossref
Qingyu Lin, Yingying Zhang, Zhequan Fu, Bingxin Hu, Zhan Si, Yanzhao Zhao, Hongcheng Shi & Dengfeng Cheng. (2020) Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor. Bioorganic & Medicinal Chemistry 28:15, pages 115577.
Crossref
N. Shrestha, A.R. Bland, R.L. Bower, R.J. Rosengren & J.C. Ashton. (2020) Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer. Journal of Pharmacology and Experimental Therapeutics 374:1, pages 134-140.
Crossref
Shun Takao, Takeshi Masuda, Takahiro Yamada, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada & Noboru Hattori. (2020) The Administration of Crizotinib to a ROS1-positive Advanced Non-small Cell Lung Carcinoma Patient Under Immunosuppressive Therapy After Renal Transplantation: a Case Report腎移植後免疫抑制療法中のROS1陽性進行非小細胞肺癌に対してクリゾチニブを投与した1例. Haigan 60:3, pages 197-201.
Crossref
Ramon Andrade De Mello, Nathália Moisés Neves, Giovanna Araújo Amaral, Estela Gudin Lippo, Pedro Castelo-Branco, Daniel Humberto Pozza, Carla Chizuru Tajima & Georgios Antoniou. (2020) The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer. Journal of Clinical Medicine 9:6, pages 1918.
Crossref
Amit S. Kalgutkar & James P. Driscoll. (2020) Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?. Biochemical Pharmacology 174, pages 113796.
Crossref
Marie‐Noëlle Paludetto, Florent Puisset, Etienne Chatelut & Cécile Arellano. (2019) Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity. Medicinal Research Reviews 39:6, pages 2105-2152.
Crossref
Ching‐Hsiung Chang, Hsu‐Liang Chang, Jui‐Feng Hsu & Chih‐Jen Yang. (2019) Rifampin may decrease the efficacy of crizotinib in lung cancer treatment. The Kaohsiung Journal of Medical Sciences 35:9, pages 580-581.
Crossref
Swan Lin, Dana J. Nickens, Maulik Patel, Keith D. Wilner & Weiwei Tan. (2019) Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 84:1, pages 203-211.
Crossref
Pramod C. Nair, Ross A. McKinnon & John O. Miners. (2019) Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. Drug Metabolism and Disposition 47:6, pages 616-631.
Crossref
Johnson Segun Showande, Sharon Iyobor Igbinoba, Marena Kajula, Juho Hokkanen, Ari Tolonen, Olayemi Modupe Adegbolagun & Titilayo Oyelola Fakeye. (2019) In vitro modulation of cytochrome P450 isozymes and pharmacokinetics of caffeine by extracts of Hibiscus sabdariffa Linn calyx . Journal of Basic and Clinical Physiology and Pharmacology 30:3.
Crossref
Ryan H. Takahashi, Jae H. Chang, Jodie Pang, Xiaorong Liang & Shuguang Ma. (2019) Unequal Absorption of Radiolabeled and Nonradiolabeled Drug from the Oral Dose Leads to Incorrect Estimates of Drug Absorption and Circulating Metabolites in a Mass Balance Study. Drug Metabolism Letters 13:1, pages 37-44.
Crossref
Takeshi Hirota, Shota Muraki & Ichiro Ieiri. (2018) Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clinical Pharmacokinetics 58:4, pages 403-420.
Crossref
Alberto Puccini, Nagore I. Marín-Ramos, Francesca Bergamo, Marta Schirripa, Sara Lonardi, Heinz-Josef Lenz, Fotios Loupakis & Francesca Battaglin. (2019) Safety and Tolerability of c-MET Inhibitors in Cancer. Drug Safety 42:2, pages 211-233.
Crossref
Dasom Jung, Ji Min Han, Jeong Yee, Jae Youn Kim & Hye Sun Gwak. (2018) Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Medical Oncology 35:12.
Crossref
Xiaoyan Qi, Lin Zhao, Qiuping Zhao & Qiaoxia Xu. (2018) Simple and sensitive LC–MS/MS method for simultaneous determination of crizotinib and its major oxidative metabolite in human plasma: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 155, pages 210-215.
Crossref
Anthony B. El-Khoueiry, John Sarantopoulos, Cindy L. O’Bryant, Kristen K. Ciombor, Huiping Xu, Melissa O’Gorman, Jayeta Chakrabarti, Tiziana Usari & Bassel F. El-Rayes. (2018) Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 81:4, pages 659-670.
Crossref
Jim Zheng, Yan Xin, Jingyu Zhang, Raju Subramanian, Bernard P. Murray, J. Andrew Whitney, Matthew R. Warr, John Ling, Lisa Moorehead, Ellen Kwan, Jeffrey Hemenway, Bill J. Smith & Jeffrey A. Silverman. (2018) Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development. Drug Metabolism and Disposition 46:3, pages 237-247.
Crossref
Mika Sato-Nakai, Kosuke Kawashima, Toshito Nakagawa, Yukako Tachibana, Miyuki Yoshida, Kenji Takanashi, Peter N. Morcos, Martin Binder, David J Moore & Li Yu. (2017) Metabolites of alectinib in human: their identification and pharmacological activity. Heliyon 3:7, pages e00354.
Crossref
Weiwei Tan, Shinji Yamazaki, Theodore R. Johnson, Rong Wang, Melissa T. O’Gorman, Leonid Kirkovsky, Tanya Boutros, Nicoletta M. Brega & Akintunde Bello. (2016) Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer. Clinical Drug Investigation 37:4, pages 363-373.
Crossref
Frank M. Balis, Patrick A. Thompson, Yael P. Mosse, Susan M. Blaney, Charles G. Minard, Brenda J. Weigel & Elizabeth Fox. (2016) First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium. Cancer Chemotherapy and Pharmacology 79:1, pages 181-187.
Crossref
Yutaka Fujiwara, Akinobu Hamada, Hidenori Mizugaki, Hiroaki Aikawa, Toshiyuki Hata, Hidehito Horinouchi, Shintaro Kanda, Yasushi Goto, Kota Itahashi, Hiroshi Nokihara, Noboru Yamamoto & Yuichiro Ohe. (2016) Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB 1 polymorphism . Cancer Science 107:8, pages 1117-1123.
Crossref
Huiping Xu, Melissa O?Gorman, Weiwei Tan, Nicoletta Brega & Akintunde Bello. (2015) The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. European Journal of Clinical Pharmacology 71:12, pages 1441-1449.
Crossref
Shinji Yamazaki, Theodore R. Johnson & Bill J. Smith. (2015) Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. Drug Metabolism and Disposition 43:10, pages 1417-1429.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.